02126 JW THERAP-B
- 2.330
- +0.160+7.37%
JW THERAP-B News
Medication Junol-B (02126.HK): Preliminary clinical data on rekiolense injection for the treatment of active systemic lupus erythematosus in adult Chinese patients with active systemic lupus erythematosus announced in EULAR 2024
On May 30, Gelonghui | Pharmacomingjuno-B (02126.HK) announced the latest clinical data on patients with active systemic lupus erythematosus (“SLE”) in Chinese adults with active systemic lupus erythematosus (“SLE”) at the 2024 European Congress of Rheumatology (“EULAR 2024”). According to disclosure, systemic lupus erythematosus is a chronic autoimmune disease that causes damage to multiple organs and tissues throughout the body. According to estimates, there are about 1 million people with systemic lupus erythematosus in China, ranking first in the world in total number and second in incidence. Currently traditional treatments for systemic lupus erythematosus include cortical
Changes in Hong Kong stocks | Pharmaceutical Juno-B (02126) rose more than 8%, SLE clinical data showed good safety
Pharmaceutical Juno-B (02126) rose more than 8%. As of press release, it had risen 8.29% to HK$2.35, with a turnover of HK$2,041,800.
Featured announcements | China Coal Energy's majority shareholder proposes to pay a special dividend of 1.5 billion yuan; Lenovo Group and Saudi Sovereign Fund reach strategic cooperation
ZTE plans to use no more than 20 billion yuan of its own capital to entrust financial management; Postbank plans to transfer trust beneficiary rights and asset management plan income rights for 51.6 billion yuan.
Preliminary Clinical Data on Relma-Cel Injection in Adults With Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology c
JW (Cayman) Therapeutics Presents Trial Data From SLE Drug at Rheumatology Congress
JW (Cayman) Therapeutics (HKG:2126) presented the preliminary clinical data on its relmacabtagene autoleucel injection trial for adults in China at the 2024 European Alliance of Associations for Rheum
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
藥明巨諾-B：2023年度報告
Big benefits have arrived! Pharmacovigilance is getting stronger. What's the situation?
Yao Ming Kangde's deep participation in the US healthcare field has far surpassed congressional discussions. Some senior members of the country's biotech industry have clearly opposed the bill.
Pharmaceutical Junuo (02126.HK): Significant results in cost reduction and efficiency explore clinical applications of self-exemption
The 2023 results are in line with our expectations. The company announced the 2023 results: revenue of 174 million yuan, up 19.3% year on year; net profit to mother - 768 million yuan. The 2023 results are in line with our expectations. Development trend Benuo
JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023
JW (Cayman) Therapeutics (HKG:2126) recorded a narrower attributable loss for the year ended Dec. 31, 2023, of 768 million yuan from 846.1 million yuan during the year-ago period, a Tuesday filing on
Pharmaceutical Juno-B (02126) released annual results, gross profit of 882.19 million yuan, a year-on-year increase of 50.14%
Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023. The group...
JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING
The US BIO organization announced the exclusion of Medicinal Kangde membership. The reason behind this is a piece of legislation
Last week, the US Senate Homeland Security Committee passed the Biosafety Act, which prohibits federal agencies from signing contracts with foreign biotechnology companies, including Pharmacovigilus, on national security grounds.
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Pharmaceutical Juno-B (02126.HK) held a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 Pharmaceutical Juno-B (02126.HK) announced that the company would like to hold a board meeting on March 20, 2024 (Wednesday) to (i) consider and approve the Group's audited consolidated results for the year ended 31 December 2023 and their release; (ii) the proposed final dividend (if any); and (iii) address any other matters.
JW THERAP-B: NOTICE OF BOARD MEETING
The US Senate version of the Biosafety Act was passed at a hearing last night. What is the situation, and how should the Pharmacovigilance Department respond?
The industry believes that the bill may be fiercely discussed and repeatedly revised in the Senate and House of Representatives, and that relevant companies should “think from the bottom line.”
Express News | US Senate version of “Biosafety Act” passed hearing House bill hearing will be held soon
Analysis
Price Target
No Data
